RVMD
Revolution Medicines Inc
$
35.260
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
35.600
Open
34.820
VWAP
35.04
Vol
2.52M
Mkt Cap
6.59B
Low
34.210
Amount
88.19M
EV/EBITDA(TTM)
--
Total Shares
164.99M
EV
4.35B
EV/OCF(TTM)
--
P/S(TTM)
--
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
Show More
Get winning stock picks in minutes
10 Analyst Rating
90.61% Upside
Wall Street analysts forecast RVMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVMD is 67.21 USD with a low forecast of 37.91 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
0 Hold
0 Sell
Strong Buy
90.61% Upside
Current: 35.260
Low
37.91
Averages
67.21
High
80.00
90.61% Upside
Current: 35.260
Low
37.91
Averages
67.21
High
80.00
Goldman Sachs
Buy
initiated
$65
2025-07-15
Reason
Goldman Sachs
Price Target
$65
2025-07-15
initiated
Buy
Reason
Goldman Sachs initiated coverage of Revolution Medicines with a Buy rating and $65 price target. The firm says Revolution is a late stage clinical precision oncology company focused on developing a portfolio of RAS(On) inhibitors. Goldman sees blockbuster and underappreciated at current share levels commercial opportunities for the company.
H.C. Wainwright
Robert Burns
Buy
downgrade
$73 -> $72
2025-05-14
Reason
H.C. Wainwright
Robert Burns
Price Target
$73 -> $72
2025-05-14
downgrade
Buy
Reason
H.C. Wainwright analyst Robert Burns lowered the firm's price target on Revolution Medicines to $72 from $73 and keeps a Buy rating on the shares following the Q1 report. The firm is factoring in higher operating expenses moving forward.
Guggenheim
Michael Schmidt
Buy
downgrade
$87 -> $80
2025-05-08
Reason
Guggenheim
Michael Schmidt
Price Target
$87 -> $80
2025-05-08
downgrade
Buy
Reason
Guggenheim analyst Michael Schmidt lowered the firm's price target on Revolution Medicines to $80 from $87 and keeps a Buy rating on the shares after the company reported Q1 results and provided a pipeline update that provided additional visibility on its potential clinical development strategy for multi-RAS inhibitor daraxonrasib and G12C-selective RAS inhibitor elironrasib in first-line non-small cell lung cancer.
Oppenheimer
Oppenheimer
Outperform
maintain
$70 -> $75
2025-05-08
Reason
Oppenheimer
Oppenheimer
Price Target
$70 -> $75
2025-05-08
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Revolution Medicines to $75 from $70 and keeps an Outperform rating on the shares. The firm notes that following the recent update describing Revolution Medicines' confidence in owning the PDAC space, the company's Q1 update, supported by a wealth of promising clinical results, further extends the potential dominance to NSCLC.
Needham
Ami Fadia
Strong Buy
Reiterates
$59
2025-04-08
Reason
Needham
Ami Fadia
Price Target
$59
2025-04-08
Reiterates
Strong Buy
Reason
Stifel
Benjamin Burnett
Strong Buy
Maintains
$78 → $64
2025-04-01
Reason
Stifel
Benjamin Burnett
Price Target
$78 → $64
2025-04-01
Maintains
Strong Buy
Reason
Stifel analyst Benjamin Burnett lowered the firm's price target on Revolution Medicines to $64 from $78 and keeps a Buy rating on the shares. Accounting the intellectual property runway, competition and historical oncology drug launches, the firm believes that the companies four opportunities combined are worth upwards of $69 per share, but it now includes a more conservative view of competition and duration-of-therapy, the analyst tells investors.
See All Ratings
Get winning stock picks in minutes
Valuation Metrics
The current forward P/E ratio for Revolution Medicines Inc (RVMD.O) is -6.20, compared to its 5-year average forward P/E of -10.20. For a more detailed relative valuation and DCF analysis to assess Revolution Medicines Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-10.20
Current PE
-6.20
Overvalued PE
-5.86
Undervalued PE
-14.54
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-7.00
Current EV/EBITDA
-3.95
Overvalued EV/EBITDA
-3.45
Undervalued EV/EBITDA
-10.55
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
2181.41
Current PS
195.89
Overvalued PS
7819.58
Undervalued PS
-3456.77
Financials
Annual
Quarterly
FY2025Q2
N/A
Total Revenue
FY2025Q2
YoY :
+68.99%
-264.71M
Operating Profit
FY2025Q2
YoY :
+85.98%
-247.79M
Net Income after Tax
FY2025Q2
YoY :
+61.73%
-1.31
EPS - Diluted
FY2025Q2
YoY :
+75.55%
-229.21M
Free Cash Flow
FY2025Q2
N/A
Gross Profit Margin - %
FY2025Q2
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q2
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
839.6K
USD
4
3-6
Months
914.9K
USD
6
6-9
Months
97.4K
USD
1
0-12
Months
11.6M
USD
16
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
60.0M
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
492.6K
Volume
3
6-9
Months
1.9M
Volume
6
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
801.2K
Volume
Months
6-9
6
7.0M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
839.6K
USD
4
3-6
Months
914.9K
USD
6
6-9
Months
97.4K
USD
1
0-12
Months
11.6M
USD
16
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
60.0M
USD
Months
0-12
0
0.0
USD
Months
RVMD News & Events
Events Timeline
2025-07-24 (ET)
2025-07-24
16:02:02
Revolution Medicines publishes zoldonrasib research in Science
2025-07-23 (ET)
2025-07-23
08:04:46
Revolution Medicines announces FDA BTD to elironrasib
2025-07-09 (ET)
2025-07-09
08:18:34
Revolution Medicines announces collaboration with Iambic
Sign Up For More Events
Sign Up For More Events
News
4.0
08-07BenzingaNeedham Maintains Buy on Revolution Medicines, Lowers Price Target to $56
9.5
08-07NewsfilterRevolution Medicines, Inc. (RVMD) Q2 2025 Earnings Call Transcript
7.0
08-07SeekingAlphaRevolution Medicines outlines $1.03B–$1.09B net loss guidance for 2025 amid expanded global RAS portfolio strategy
Sign Up For More News
People Also Watch
WEX
WEX Inc
170.780
USD
+2.20%
LOAR
Loar Holdings Inc
69.770
USD
+2.44%
SATS
EchoStar Corp
28.000
USD
+1.89%
JAZZ
Jazz Pharmaceuticals PLC
113.330
USD
+2.33%
OTEX
Open Text Corp
29.490
USD
-2.42%
SUN
Sunoco LP
51.430
USD
+1.64%
RHI
Robert Half Inc
34.820
USD
+3.38%
MNSO
MINISO Group Holding Ltd
20.040
USD
-0.15%
AN
AutoNation Inc
205.370
USD
+3.40%
ONB
Old National Bancorp
21.440
USD
+4.23%
FAQ
What is Revolution Medicines Inc (RVMD) stock price today?
The current price of RVMD is 35.26 USD — it has increased 1.61 % in the last trading day.
What is Revolution Medicines Inc (RVMD)'s business?
What is the price predicton of RVMD Stock?
What is Revolution Medicines Inc (RVMD)'s revenue for the last quarter?
What is Revolution Medicines Inc (RVMD)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Revolution Medicines Inc (RVMD)'s fundamentals?
How many employees does Revolution Medicines Inc (RVMD). have?